No connection

Search Results

Corporate Score 35 Neutral

Immunome's Chief Scientist Sells Stake Amid Upcoming FDA Submission

Apr 04, 2026 23:25 UTC
IMMX
Short term

Jack Higgins, Chief Scientific Officer of Immunome, sold 9,438 shares in an open-market transaction on April 2, 2026. The sale, part of a pre-planned trading strategy, occurred as the company prepares for a key FDA submission.

  • Jack Higgins sold 9,438 shares of Immunome on April 2, 2026.
  • The sale was part of a 10b5-1 trading plan established in December 2025.
  • Higgins retained 22,000 shares directly and 3,000 shares indirectly after the transaction.
  • The sale value was approximately $204,000 based on a $21.64 per share price.
  • Immunome is preparing for an FDA submission for varegacestat in Q2 2026.
  • The transaction does not indicate immediate sentiment about the company’s prospects.

Jack Higgins, Chief Scientific Officer of Immunome (NASDAQ:IMNM), executed a sale of 9,438 shares of common stock on April 2, 2026, as disclosed in an SEC Form 4 filing. The transaction, valued at approximately $204,000 based on the reported price of $21.64 per share, represented 30.02% of Higgins’s holdings at the time. Following the sale, Higgins retained a direct holding of 22,000 shares, with an additional 3,000 shares held indirectly. The sale was conducted under a 10b5-1 trading plan established in December 2025, indicating a pre-determined strategy for financial diversification rather than reactive market timing. Higgins, who previously spent 11 years at Molecular Templates and completed a fellowship in tumor immunology at the National Cancer Institute, remains significantly invested in Immunome, with a post-transaction direct position valued at roughly $480,000 at the April 2 market close. The transaction occurred as Immunome advances its pipeline, including the planned FDA submission for varegacestat in Q2 2026 following the Phase 3 RINGSIDE trial’s primary endpoint success in December 2025. Investors are advised to focus on these upcoming milestones rather than the pre-planned executive sale, which does not reflect immediate sentiment about the company’s prospects. The broader market impact of the sale is limited, as it primarily affects specific positions rather than the company’s overall trajectory.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 25

Striking JBS workers to return to Colorado plant on promise of talks

Apr 05, 03:12

Score 35

Maze Therapeutics' CMO Sells Entire Stock Stake Amid Market Volatility

Apr 04, 23:56

Score 25

Photronics Director Sells 10,000 Shares Amid Strong Stock Performance

Apr 04, 21:56

Score 25

Brookfield Corporation Embraces Berkshire Hathaway's Investment Model

Apr 04, 21:35

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile